Structure of acetylcholinesterase complexed with E2020 (Ariceptρ): Implications for the design of new anti-Alzheimer drugs

Structure

Volumn 7, Issue 3, 1999, Pages 297-307

  Kryger, Gitay ^a   Silman, Israel ^a   Sussman, Joel L ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Crystal structure; Drug protein complex

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; ENZYME ACTIVE SITE; PRIORITY JOURNAL;

EID: 0033103478     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(99)80040-9     Document Type: Article

References (58)

1. Drachmen, D.A. & Leavitt, J. (1974). Human memory and the cholinergic system. Arch. Neurol. 30, 113-121.
2. Bowen, D.M., & Davison, A.N., et al., (1983). Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J. Neurochem. 41, 266-272.
3. Bartus, R.T., Dean, R.L., Beer, B. & Lippa, A.S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
4. Dunnett, S.B. & Fibiger, H.C. (1993). Role of forebrain cholinergic systems in learning and memory: Relevance to the cognitive deficits of aging and Alzheimer's dementia. Prog. Brain Res. 98, 413-420.
5. Weinstock, M. (1997). Possible role of the cholinergic system and disease models. J. Neural Transm. Suppl. 49, 93-102.
6. Becker, R., Giacobini, E., Elble, R., McIlhany, M. & Sherman, K. (1988). Potential pharmacotherapy of Alzheimer's disease. A comparison of various forms of physostigmine administration. Acta Neurol. Scand. Suppl. 116, 19-32.
7. Zhang, R.W., & Yang, R.M., et al., (1991). Drug evaluation of huperzine A in the treatment of senile memory disorders. Acta Pharm. Sinica 12, 250-252.
8. Weinstock, M., Razin, M., Chorev, M. & Enz, A. (1994). Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J. Neural Transm. Suppl. 43, 219-225.
9. Knopman, D.S. (1998). Metrifonate for Alzheimer's disease: Is the next cholinesterase inhibitor better? Neurology 50, 1203-1206.
10. Inestrosa, N.C., & Garrido, J., et al., (1996). Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16, 881-891.
11. Reyes, A.E., & Inestrosa, N.C., et al., (1997). A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem. Biophys. Res. Commun. 232, 652-655.
12. Davis, K.L. & Powchik, P. (1995). Tacrine. Lancet 345, 625-630.
13. Nightingale, S.L. (1997). Donepezil approved for treatment of Alzheimer's disease. JAMA 277, 10.
14. Kawakami, Y., Inoue, A., Kawai, T., Wakita, M., Sugimoto, H. & Hopfinger, A.J. (1996). The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg. Med. Chem. 4, 1429-1446.
15. Cardozo, M.G., Imura, Y., Sugimoto, H., Yamanishi, Y. & Hopfinger, A.J. (1992). QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J. Med. Chem. 35, 584-589.
16. Cardozo, M.G., Kawai, T., Imura, Y., Sugimoto, H., Yamanishi, Y. & Hopfinger, A.J. (1992). Conformational analyses and molecular-shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J. Med. Chem. 35, 590-601.
17. Sussman, J.L, & Silman, I., et al., (1991). Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science 253, 872-879.
18. Rupniak, N.M., Tye, S.J. & Field, M.J. (1997). Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology Berlin 131, 406-410.
19. Galli, A., Mori, F., Benini, L. & Cacciarelli, N. (1994). Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020. Eur. J. Pharmacol. 270, 189-193.
20. Thomsen, T. & Kewitz, H. (1990). Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci. 46, 1553-1558.
21. Loewenstein, Y., Gnatt, A., Neville, L.F. & Soreq, H. (1993). Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands. J. Mol. Biol. 234, 289-296.
22. Sugimoto, H., Imura, Y., Yamanishi, Y. & Yamatsu, K. (1995). Synthesis and structure-activity-relationships of acetylcholinesterase inhibitors - 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38, 4821-4829.
23. Cheng, D.H., Ren, H. & Tang, X.C. (1996). Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 8, 97-101.
24. Villalobos, A., & Frost White, W., et al., (1995). 5,7-dihydro-3-[2-[1 - (phenylmethyl)-4-piperidinyl]ethyl]-6H- pyrrolo[3,2-f]-1,2-benzisoxazol-6-one: A potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety. J. Med Chem. 38, 2802-2808.
25. Pang, Y.P. & Kozikowski, A.P. (1994). Prediction of the binding site of 1 -benzyl-4-[(5,6-dimethoxy-1 -indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program. J. Comput. Aided Mol. Des. 8, 683-693.
26. Harel, M., & Silman, I., et al., (1992). Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc. Natl Acad. Sci. USA 89, 10827-10831.
27. Schumacher, M., & Taylor, P., et al., (1986). Primary structure of Torpedo californica acetylcholinesterase deduced from its cDna sequence. Nature 319, 407-409.
28. Harel, M., & Sussman, J.L., et al., (1993). Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl Acad. Sci. USA 90, 9031-9035.
29. Harel, M., Quinn, D.M., Nair, H.K., Silman, I. & Sussman, J.L. (1996). The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. J. Am. Chem. Soc. 118, 2340-2346.
30. Levitt, M. & Perutz, M.F. (1988). Aromatic rings act as hydrogen bond acceptors. J. Mol. Biol. 201, 751-754.
31. Burley, S.K. & Petsko, G.A. (1986). Amino-aromatic interactions in proteins. FEBS Lett. 203, 139-143.
32. Inoue, A., Kawai, T., Wakita, M., Imura, Y., Sugimoto, H. & Kawakami, Y. (1996). The simulated binding of (+/-)-2,3-dihydro-5,6-dimethoxy- 2-[(1-(phenylmethyl)-4-piperidinyl)methyl]-1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses. J. Med. Chem. 39, 4460-4470.
33. Verdonk, M.L., Boks, G.J., Kooijman, H., Kanters, J.A. & Kroon, J. (1993). Stereochemistry of charged nitrogen-aromatic interactions and its involvement in ligand-receptor binding. J. Comput. Aided Mol. Des. 7, 173-182.
34. Dougherty, D. (1996). Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp. Science 271, 163-168.
35. Biosym (1993). InsightII. Biosym Technologies San Diego.
36. Raves, M.L., Harel, M., Pang, Y.P., Silman, I., Kozikowski, A.P. & Sussman, J.L. (1997). Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 4, 57-63.
37. Shafferman, A., & Ariel, N., et al., (1992). Substrate inhibition of acetylcholinesterase: Residues affecting signal transduction from the surface to the catalytic center. EMBO J. 11, 3561-3568.
38. Ordentlich, A., & Shafferman, A., et al., (1993). Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. J. Biol. Chem. 268, 17083-17095.
39. Radic, Z., Pickering, N.A., Vellom, D.C., Camp, S. & Taylor, P. (1993). Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 32, 12074-12084.
40. Antosiewicz, J., Wlodek, S.T. & McCammon, J.A. (1996). Acetylcholinesterase: Role of the enzyme's charge distribution in steering charged ligands toward the active site. Biopolymers 39, 85-94.
41. Zhou, H.X., Wlodek, S.T. & McCammon, J.A. (1998). Conformation gating as a mechanism for enzyme specificity. Proc. Natl Acad. Sci. USA 95, 9280-9283.
42. Shah, R.R. (1993). Clinical pharmacokinetics: Current requirements and future perspectives from a regulatory point of view. Xenobiotica 23, 1159-1193.
43. Nation, R.L. (1989). Enantioselective drug analysis: Problems and resolutions. Clin. Exp. Pharmacol. Physiol. 16, 471-477.
44. Barnard, E.A. (1974). Neuromuscular transmission - enzymatic destruction of acetylcholine. In The Peripheral Nervous System. (Hubbard, J.I., ed.), pp. 201-224, Plenum, NY.
45. Baron, P., Harel, M., Millard, C., Enz, A., Sussman, J.L. & Silman, I. (1998). Kinetic and X-ray crystallographic studies of the binding of ENA-713 to Torpedo californica acetylcholinesterase (TcAChE). In Structure and Function of Cholinesterases and Related Proteins. (Doctor, BP, Quinn, DM, Rotundo, RL & Taylor, P, eds), pp. 373-374, Plenum, NY.
46. Bourne, Y., Taylor, P., Kanter, J.R., Bougis, P.E. & Marchot, P. (1998). Crystal structure of mouse acetylcholinesterse. In Structure and Function of Cholinesterases and Related Proteins. (Doctor, B.P., Quinn, D.M., Rotundo, R.L. & Taylor, P., eds), pp. 315-322, Plenum, NY.
47. Kryger, G., & Sussman, J.L., et al., (1998). 3D structure of a complex of human recombinant acetylcholinesterase with fasciculin-II at 2.7 å resolution. In Structure and Function of Cholinesterases and Related Proteins. (Doctor, B.P., Quinn, D.M., Rotundo, R.L. & Taylor, P., eds), pp. 323-326, Plenum, NY.
48. Greenblatt, H., & Sussman, J.L., et al., (1998). Crystal structures of complexes of E2020 related compounds with Torpedo acetylcholinesterase. In Structure and Function of Cholinesterases and Related Proteins. (Doctor, B.P., Quinn, D.M., Rotundo, R.L. & Taylor, P., eds), p. 371, Plenum, NY.
49. Kryger, G., & Harel, M., et al., (1998). Structural studies on human and insect acetylcholinesterase. Abstract from The Sixth International Meeting on Cholinesterases, La Jolla, CA, p. 14.
50. Hope, H. (1988). Cryocrystallography of biological macromolecules: A generally applicable method. Acta Crystallogr. B 44, 22-26.
51. Ravelli, R.B.G., Sweet, R.M., Skinner, J.M., Duisenberg, A.J.M. & Kroon, J. (1997). STRATEGY: A program to optimize the starting spindle angle and scan range for X-ray data collection. J. Appl. Crystallogr. 30, 551-554.
52. Otwinowski, Z. (1993). Oscillation data reduction program. In Proceedings of the CCP4 Study Weekend: Data Collection and Processing. (Sawyer, L., Isaacs, N. & Bailey, S., eds), pp. 56-62, SERC, Daresbury.
53. Brünger, A.T., Kuriyan, J. & Karplus, M. (1987). Crystallographic R factor refinement by molecular dynamics. Science 235, 458-460.
54. Jones, T.A., Zou, J.Y., Cowan, S.W. & Kjeldgaard, M. (1991). Improved methods for the building of protein models in electron density maps and the location of errors in these models. In Crystallographic Computing. (Moras, D., Podany, A.D. & Thierry, J.C., eds), pp. 413-432, Oxford Univ. Press, Oxford.
55. Kleywegt, G.J. & Jones, T.A. (1996). Efficient rebuilding of protein structures. Acta Crystallogr. D 52, 829-832.
56. Laskowski, R.A., Macarthur, M.W., Moss, D. & Thornton, J.M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291.
57. Vriend, G. (1990). WHAT IF: A molecular modelling and drug design program. J. Mol. Graph. 8, 52-56.
58. Laskowski, R.A. (1995). SURFNET: A program for visualizing molecular surfaces, cavities and intermolecular interactions. J. Mol. Graph. 13, 323-330.